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The standard treatment for parotid tumours is parotidec-
tomy (partial or total) with sparing of the facial nerve when-
ever possible. The spectrum of parotid neoplasms requiring 
parotidectomy has been reported extensively in the European 
and American literature.1,2 There have been a few reports of 
pathology seen in some parts of Africa,3-6 but the spectrum of 
parotid disease in southern Africa has not been reported.
Parotidectomy is most commonly performed for benign 
tumours, of which pleomorphic adenoma and Warthin’s 
tumour are the most common. The disease spectrum dif-
fers in the African population compared to that of the West, 
with an increased ratio of malignant to benign tumours in 
Africa, and Warthin’s tumours occurring less commonly.3-6 
Metastatic cutaneous squamous cell carcinoma (SCC) has 
been shown to be a common cause of parotidectomy in the 
Australian population.7,8 South Africa also has a high inci-
dence of skin cancer, and would presumably reflect this in its 
spectrum of parotid disease.
The extent of preoperative investigation for parotid 
tumours is a controversial issue, as fine-needle aspiration 
biopsy may be unhelpful, and radiological investigation, 
especially for benign tumours, often does little to add to the 
diagnosis and management. 
Facial palsy is the most important and disfiguring conse-
quence or complication following parotidectomy. Studies 
have shown that immediate facial nerve dysfunction follow-
ing parotid surgery is common (46%), but that permanent 
dysfunction is uncommon (4%).9 The reported incidence of 
long-term dysfunction is higher in revision cases and with 
extended (subtotal or total) parotidectomy.10
This study details the experience of the second author 
(J.J.F.) with parotid surgery over the past 10 years.
Objectives
The study aimed to: (i) review the University of Cape Town 
experience with parotidectomy; (ii) report on the histology of 
parotid disease requiring parotidectomy; (iii) discuss special 
investigations in the management of parotid disease; and 
(iv) describe the consequences and complications following 
parotidectomy.
Materials and methods
A retrospective review was done of all parotidectomies per-
formed under the care of one ENT (ear, nose and throat) 
surgeon (J.J.F.). These operations were done over a period 
of 10 years (1994 - 2004) at Groote Schuur Hospital, Cape 
Town. Surgery done in both the private and public health 
sectors was included in the review. At the University of Cape 
Town all parotidectomies are performed by the Division of 
Otolaryngology. Data were collected from a retrospective 
chart review. 
Results
Between 1994 and 2004, 199 parotidectomies were per-
formed on 197 patients. Two patients had bilateral parotidec-
tomies. The clinical records of 7 patients were incomplete. 
Pathology
Histological results were available for 196/199 parotidecto-
mies (Table I). Tumours were benign in 119 patients (61%) 
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Summary
Background. The spectrum of parotid disease in southern 
Africa has not previously been reported.
Methods. A review of all parotidectomies performed by 
a single surgeon over a period of 10 years (1994 - 2004) in 
Cape Town, South Africa, is presented. Data were collected 
from a retrospective chart review. 
Results. One hundred and ninety-nine parotidectomies 
were performed and 196 pathology reports were reviewed. 
Pleomorphic adenoma was the most common benign tu-
mour and metastatic cutaneous squamous cell carcinoma 
(SCC) was the most common malignancy. Warthin’s tu-
mour had an equal gender distribution. Forty-five per cent 
of parotid tumours in males were malignant. The sensitivity, 
specificity and accuracy of fine-needle aspiration cytology 
(FNAC) in diagnosing malignancy were 73%, 98% and 94% 
respectively. 
Conclusions. In South African males almost half of parotid 
tumours are malignant. Warthin’s tumours are less common 
in Africa than in the West, and did not show a male pre-
ponderance. FNAC is a highly reliable method of excluding 
malignancy. 
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and malignant in 53 (27%) The ratio of benign to malignant 
tumours was 2.25:1. Twenty-four patients (12%) had non-
neoplastic disease.
Sixty-nine per cent of neoplasms were benign. Pleomorphic 
adenoma (42%) and Warthin’s tumour (8%) were the most 
common benign tumours, and accounted for 70% and 13% 
of benign parotid tumours respectively. One patient had 
bilateral Warthin’s tumours and underwent bilateral paroti-
dectomy. Four patients had benign lympho-epithelial lesions. 
Three of these patients were HIV-negative and the lesions 
were unilateral. One HIV-positive patient underwent paroti-
dectomy for cosmetic reasons. The lesions recurred and bilat-
eral low-dose radiotherapy was given. Other lesions included 
2 lymphangiomas and 2 neurofibromas. One case was a 20-
year-old girl with neurofibromatosis type 1, and a plexiform 
neurofibroma of the parotid gland. She had a 14-year history 
of a right parotid mass, which was particularly disfiguring. 
The plexiform neurofibroma of the parotid was removed by 
superficial parotidectomy with sparing of the facial nerve.
Thirty-one per cent of tumours were malignant. Metastatic 
cutaneous SCC was the most common malignancy and 
accounted for 22% of parotid malignancies. Metastatic mela-
noma accounted for 15% of parotid malignancies.  Primary 
parotid malignancies accounted for 16% of parotid tumours. 
Muco-epidermoid carcinoma accounted for 30% of primary 
parotid malignancy, followed by acinic cell carcinoma (27%), 
lymphoma (10%), adenoid cystic carcinoma (10%) and 
primary SCC (7%). There were 3 lymphomas, 2 primary 
parotid SCCs and 1 undifferentiated carcinoma. There were 
no cases of carcinoma ex-pleomorphic adenoma.
Age
The age distribution of patients undergoing parotidectomy is 
summarised in Table II. The age difference between patients 
with benign and malignant disease, both primary and meta-
static, was statistically significant. Benign tumours occurred 
at a mean age of 45 years, while malignant tumours occurred 
at 57 years.
Gender
The gender distribution for specific tumours is given in Table 
III. Parotidectomies were performed in 118 females (59%) 
and 81 males (41%). Benign tumours occurred more com-
monly in females and malignant tumours more commonly in 
males. Primary parotid malignancies were more common in 
females and metastatic malignancies more common in males. 
Pleomorphic adenoma, Warthin’s tumours and muco-epider-
moid carcinoma occurred with similar frequency in males 
and females. Metastatic SCC was more common in males, 
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Table I. HIsTology of paroTId dIsease  
(N = 196)
Histological findings     No. % 
benign disease (N = 119)
pleomorphic adenoma    83 42
Warthin’s tumour     16   8
Monomorphic adenoma*      7   3
lipoma       5   3
benign lympho-epithelial  
lesions       4   2
Neurofibroma       2   1
lymphangioma       2   1
Malignant disease (N = 53) 
  Metastatic cutaneous sCC    12   6
Muco-epidermoid 
carcinoma       9   5
Cutaneous melanoma      8   4
acinic cell carcinoma      8   4
lymphoma       3   2
adenoid cystic carcinoma      3   2
primary sCC       2   1
Undifferentiated  
carcinoma       2   1
Metastatic oral cavity sCC      2   1
Metastatic maxillary sinus 
sCC       1   0.5
Malignant fibrous  
histiocytosis        1   0.5
adenocarcinoma       1   0.5
retinoblastoma       1   0.5
Non-neoplastic disease  
(N = 24) 
  Chronic sialadenitis     10    5
parotid trauma       4    2
sialosis       3    2
branchial cyst       2   1
Tuberculosis       1   0.5
Castleman’s disease      1   0.5
sarcoidosis       1   0.5
Myofibroblastic 
 proliferation       1   0.5
fatty infiltration       1   0.5 
*Includes basal cell adenoma.
SCC = squamous cell carcinoma.
Table II. age of paroTIdeCToMy paTIeNTs
                    Age (yrs)
Pathology        No.   Range          Mean  Compared with benign
all cases       194*    6 - 93         47.9
benign       117*  18 - 93         45.2
Malignant         53    6 - 84         57.3 p = 0.0001
  primary         28  13 - 78         53.6 p = 0.0163
  secondary         25    6 - 84         60.8 p = 0.0001 
*Age not known for 2 patients.
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while melanoma had an equal gender distribution. An impor-
tant observation is that 45% of parotid tumours in males 
were malignant, either primary or metastatic. Data on ethnic-
ity were incomplete so no analysis was done in this regard. 
Preoperative investigations
Preoperative investigations are listed in Table IV. Many of 
these investigations were done by referring physicians, and 
would not have been requested by the primary surgeon. 
Trucut biopsy was generally reserved for patients with locally 
advanced disease that would necessitate either facial nerve or 
extensive local resection.
Fine-needle aspiration cytology (FNAC)
The most important answer that FNAC should provide for 
the surgeon is whether the mass is benign or malignant. 
FNAC was done in 112 (57%) patients, principally by the 
referring doctors. Specimens were reported as being ‘inad-
equate/indeterminate’ in 45/112 cases (40%). There was 
one false-positive diagnosis of malignancy, with a Warthin’s 
tumour misdiagnosed as muco-epidermoid carcinoma. Three 
false-negatives for malignancy (4%) were 2 monomorphic 
adenomas diagnosed as high-grade muco-epidermoid car-
cinoma and acinic cell carcinoma, and a benign cyst diag-
nosed as acinic cell carcinoma.  The diagnostic accuracy of 
‘adequate’ FNAC samples is summarised in Table V.  The 
sensitivity and specificity in diagnosing malignancy were 73% 
and 98% respectively. The accuracy in diagnosing benign and 
malignant tumours was 94%.
Morbidity
One hundred and ninety-two patient folders were reviewed 
for surgical morbidity (Table VI).  Frey’s syndrome was not 
evaluated as patients were not recalled, and without direct 
questioning the incidence would probably be underreported.
One facial nerve branch (0.5%) had been divided inad-
vertently. It was primarily repaired and the patient made a 
full recovery at 6 months. The other permanent palsies (N = 
18) occurred after intentional sacrifice of the nerve as it was 
involved with the tumour. In 4 cases of benign disease, 1 of 
which was for recurrent pleomorphic adenoma, facial nerve 
branches (marginal mandibular (N = 3), superior division 
(N = 1)) were sacrificed. The superior division was repaired 
with a greater auricular nerve graft, the mandibular branches 
were not repaired. Facial nerve resection, either complete or 
partial, was required in 29% (8/28) of primary parotid carci-
noma and 24% (6/25) of metastatic malignancy. Facial nerve 
resection was done in 100% of primary SCC, 50% of undif-
ferentiated, 38% of muco-epidermoid and 25% of acinic cell 
carcinomas.
Procedures
The procedures performed are presented in Table VII. Flaps 
were required in 10 patients (radial forearm, antero-lateral 
thigh, and rectus abdominus free microvascular flaps, and 
latissimus dorsi pedicled flap).
Table III. dIsTrIbUTIoN of MosT CoMMoN TUMoUrs by geNder (N = 172)
Tumour type  Male (N = 64)   Female (N = 108)   p-value
 
benign (N (%))  35 (55)   84 (78)    0.0002
Malignant (N (%))  29 (45)   24 (22)    0.0002
primary parotid   12 (41)   18 (75)    0.0069
malignancy
Metastatic parotid  17 (59)     6 (25)    0.0069
malignancy
benign (N (%))  35 (55)   84 (78)
pleomorphic adenoma 23 (66)   60 (71)    0.2676
Warthin’s tumour    5 (14)   11 (13)    0.8572
Malignant primary   29 (45)   24 (22)
salivary (N (%))
Muco-epidermoid    5 (17)     4 (16)    0.4761
acinic cell    2   (7)     6 (25)    0.0336
Malignant metastasis  29 (45)   24 (22)
(N (%))
Metastatic squamous  12 (41)     3 (13)    0.0102
cell carcinoma
Metastatic cutaneous    5 (17)     3 (13)    0.3156 
melanoma
Table IV. preoperaTIVe exaMINaTIoNs 
 (N = 196)
Investigation  No.  %
fine-needle   112  57 
aspiration cytology  
Computed tomography   73  37
Ultrasound scan    37  19
open biopsy    19  10
Trucut biopsy    14    7
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Discussion
The incidence of parotid disease in the literature is estimated 
at 3 - 4 /100 000/year.11,12 We present a review of the experi-
ence of a single surgeon (J.J.F.) with parotid surgery over a 
10-year period in a southern African setting. In our series 
parotidectomy was most frequently performed in the 4th 
decade for benign disease and the 5th decade for malignant 
disease. Parotid malignancies occurred at a mean age of 
57 years, which is similar to the findings of a large series of 
1 432 patients reported by Renehan et al.2 in the UK. This 
differs from findings from central Africa where parotid 
tumours, both benign and malignant, occurred predominant-
ly in the 3rd decade of life.3-6
Benign neoplasms
Benign tumours occurred more commonly in females, 
and malignant tumours more commonly in males. Benign 
tumours comprised 69% of the parotid neoplasms, and pleo-
morphic adenoma and Warthin’s tumour accounted for 48% 
and 9% of parotid tumours. Warthin’s tumour occurred with 
similar frequency in males and females. This differs from all 
previous publications, which reported Warthin’s tumour to 
be predominantly a male disease, occurring 2.2 - 7 times 
more frequently in males.2,9,10 Warthin’s tumours are very 
rare in other African series.3-6 They accounted for 0/82 parot-
id tumours in a series from Tanzania.3 Warthin’s tumours 
accounted for 9% of parotid tumours in our series, which 
is much less than the 15 - 22% reported in most Western 
series.1,2,8,11,12
Malignant neoplasms
Malignant tumours accounted for 31% of parotid tumours. 
However 45% of parotid tumours in males were malignant, 
either primary or metastatic. Table VIII compares our results 
with parotid malignancies in 3 other settings (USA, Australia 
and Africa).1,3,7 
Studies from Uganda and Tanzania reported malignancy 
in 46% and 47% of salivary gland tumours respectively.3,4 
In most Western series parotid malignancies make up only 
11 - 28% of parotid tumours.1,2,11,12 The exception is Australia 
where 44 - 48% of parotid tumours are malignant.7,8 A large 
proportion of these tumours are metastatic malignancy (75% 
of parotid malignancy), with cutaneous malignancy (SCC 
and melanoma) being most common.
Cutaneous metastases 
Metastatic malignancy accounted for 45% of parotid malig-
nancy in our series. Metastatic cutaneous SCC (22%) was 
the most common malignant tumour. It is predominantly a 
male disease, occurring 5 times as frequently as in females 
in our study. This would be in keeping with the male pre-
ponderance of SCC of the skin in South Africa.13 Cutaneous 
melanoma accounted for 15% of malignant tumours. A high 
incidence of cutaneous malignancy as a reason for paroti-
dectomy has been reported in the Australian literature.7,8 
O’ Brien in Sydney,7 and Bora et al.8 in Brisbane, reported 
cutaneous SCC in 46% and 48% of malignant tumours. 
Melanoma accounted for 25% and 7% in the same series.
Primary malignancy
In our series, muco-epidermoid carcinoma was the most 
common, followed by acinic cell carcinoma, lymphoma and 
adenoid cystic carcinoma. In other African series malignan-
cies were dominated by muco-epidermoid and adenoid cystic 
Table V. fINe-Needle aspIraTIoN CyTology 
(fNaC) IN paroTId TUMoUrs (N = 67)
  Pathology
FNAC                    Malignant         Benign         Total 
Malignant                 8                       1                  9
Not malignant          3                     55                58
Total                      11                     56                67
Table VI. CoNseqUeNCes aNd CoMplICaTIoNs 
of paroTIdeCToMy (N = 192)
Consequences/ 
complications         N                       %
facial nerve palsy          84                       44
Temporary palsy        65                       34
benign disease        49                       26
Malignant disease          16                         8
permanent palsy        19                       10
benign disease          4                         2
Malignant disease          15                         8
Wound infection          9                         5
seroma          6                         3
Haematoma          6                         3
salivary fistula          4                         2
Table VII. Types of paroTIdeCToMy, addITIoNal sUrgery (N = 197)
Procedure   Number   %
partial parotidectomy       152   77
Total parotidectomy with sparing facial nerve        24   12
Total parotidectomy with partial facial         17     9
nerve resection 
Total parotidectomy with total facial          4     2
nerve resection
Neck dissections          27   14
free/pedicled flaps          10     5
Temporal bone resection           4     2
Maxillectomy            2     1
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carcinoma.3-6 It is possible that the incidence of lymphoma 
might increase with the AIDS pandemic in southern Africa. 
In Australia, primary malignant tumours were dominated 
by adenocarcinoma and muco-epidermoid carcinoma.7,8 In 
Europe and the USA the most common parotid malignancies 
are muco-epidermoid, adenoid cystic or acinic cell carci-
noma.1,2,11,12 
Preoperative investigations
Preoperative special investigations of a parotid lump should 
only be requested if this is likely to change management. 
In the developing world setting one also needs to consider 
pathology such as tuberculosis and HIV-related parotid dis-
ease.
In benign disease radiological investigation may distinguish 
a tumour in the deep lobe from one in the superficial lobe, 
and it may help to distinguish solid from cystic lesions, but 
other than this radiological investigation is of little benefit. We 
employ computed tomogaphy (CT) and magnetic resonance 
imaging (MRI) to assist with: surgical planning in clinically 
malignant tumours (fixity, pain, VIIn weakness, trismus), 
facial nerve paralysis to assess extension along the fallopian 
canal, patients with suspected extension to parapharyngeal 
space, and to determine the extent of recurrent pleomorphic 
adenoma.  The high incidence of imaging studies in benign 
disease in our study can be attributed to the fact that non-
ENT specialists requested most of these before referral.
We employ FNAC only when a diagnosis of malignancy 
might change our surgical approach, e.g. suspected cutane-
ous metastatic disease, as such patients require elective neck 
dissection,7 when facial nerve sacrifice might be required, 
or when a non-surgical diagnosis such as tuberculosis, sar-
coidosis or lymphoma is considered. The low yield (60%) of 
material suitable for cytological diagnosis is likely to be due 
to poor training and sampling technique. The accuracy of 
FNAC in predicting whether a mass is benign or malignant 
ranges from 81% to 98%.14-18 The accuracy in our series 
was 94%. Crucially, the specificity of excluding a malignant 
tumour was 98%. This is in keeping with the results reported 
by Chan et al.,14 Seethala et al.15 and Frable and Frable.16 We 
do trucut biopsies for inoperable tumours where a malignan-
cy is suspected irrespective of the FNAC result. In our series 
of 14 trucut biopsies the diagnosis of malignancy was correct 
in all cases.
Facial nerve
Facial nerve palsy is the major postoperative morbidity asso-
ciated with parotidectomy. In benign disease postoperative 
temporary facial palsy has been reported at 46 - 63%.19-21 
The reported rate of permanent paralysis with benign disease 
is 3 - 4%.2,19-21 In malignant disease the incidence of perma-
nent facial palsy has been reported to be as high as 36%.2 In 
our series temporary facial palsy occurred in 34% of benign 
disease, and the rate of permanent palsy (selected branches 
only) was 3% for benign disease and 8% for malignant dis-
ease. There was only one inadvertent facial nerve (frontal 
branch) injury; this was recognised and immediately repaired 
with good outcome. The other permanent palsies occurred 
when facial branches were intentionally sacrificed because of 
tumour involvement.
We do not advocate routine use of a facial nerve monitor. 
We use the facial nerve monitor only for revision parotid 
surgery or for massive tumours when the normal anatomical 
landmarks of the facial nerve might be obscured. We always 
use operating loupes (x 2.5), and avoid muscle paralysis. It is 
useful to stimulate the trunk of the facial nerve at conclusion 
of surgery to confirm that the nerve and its branches are all 
intact, and to be able to reassure the patient with postopera-
tive facial weakness that it is temporary.
Conclusions
In conclusion: (i) almost half of parotid tumours are malig-
nant, either primary or metastatic, in South Africa (males), 
Africa and Australia; (ii) Warthin’s tumours are less common 
in Africa than in the West, and in our series did not show a 
male preponderance; (iii) adequate sampling for FNAC is 
operator-dependent and is likely to improve with training; 
(iv) FNAC is a highly reliable method of excluding malig-
nancy; and (v) routine facial nerve monitoring is unlikely 
to improve facial nerve preservation rates in the hands of a 
surgeon versed in the surgical anatomy of the facial nerve. 
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